Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

NCT03695185 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03695185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03695185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
March 26, 2019
Completion date
January 10, 2022
Enrollment
42 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)